– “LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy” will present the most recent and robust data on LSD in patients with anxiety – – This study builds on decades of research on the effects of LSD in humans – NEW YORK, April 14, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company…


Previous articleFilament Health Announces Pre-ind Meeting With United States Food And Drug Administration
Next articlePsychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse Stock-Split; Are Magic Mushrooms Giving Investors a Bad Trip?